Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

1.84USD
9 Dec 2016
Change (% chg)

$-0.05 (-2.65%)
Prev Close
$1.89
Open
$1.92
Day's High
$1.95
Day's Low
$1.83
Volume
225,626
Avg. Vol
277,998
52-wk High
$14.10
52-wk Low
$1.51

Latest Key Developments (Source: Significant Developments)

ImmunoGen Inc gives FY 2016 guidance
Friday, 31 Jul 2015 06:30am EDT 

ImmunoGen Inc:Says that it expects FY 2016 revenues to be between $70 million and $80 million.Sees FY 2015 net loss to be between $120 million and $125 million.  Full Article

ImmunoGen Inc reaffirms FY 2015 net loss outlook, lowers revenue outlook
Friday, 24 Apr 2015 06:17am EDT 

ImmunoGen Inc:Continues to expect FY 2015 net loss between $60 and $65 million.Now expects FY 2015 revenues to be between $85 and $95 million, compared with previous guidance of between $100 and $105 million, due to changes in the expected timing of partner milestone events.  Full Article

ImmunoGen Inc and Hurricane LLC enters into royalty purchase agreement with Immunity Royalty Holdings - Form 8-K
Monday, 30 Mar 2015 08:02am EDT 

ImmunoGen Inc:Says company and its wholly owned subsidiary, Hurricane, LLC entered into a royalty purchase agreement with Immunity Royalty Holdings, L.P (purchaser)., which was formed by certain TPG Special Situations Partners’ investment funds.Transaction is subject to the satisfaction of customary closing conditions and is expected to close in early April.Purchase Agreement provides that, in consideration of the payment of $200 mln by the Purchaser to Hurricane.Purchaser will have the right to receive 100 pct of the royalty payments on commercial sales of Kadcyla (Kadcyla Royalties) arising under License Agreement with Genentech, Inc., as amended, until the Purchaser has received aggregate Kadcyla Royalties equal to $235 mln or $260 mln;.Depending on when the aggregate Kadcyla Royalties received by the Purchaser reach a specified milestone.Once the applicable threshold is met, if ever, we will thereafter receive 85 pct, and the Purchaser will receive 15 pct, of the Kadcyla Royalties for the remaining royalty term.  Full Article

Takeda Pharmaceutical announces business alliance with ImmunoGen
Monday, 23 Mar 2015 07:00pm EDT 

Takeda Pharmaceutical Co Ltd:Formed a business alliance of exclusive license of antibody-drug conjugate, which is owned by Takeda Pharmaceutical, with ImmunoGen Inc.  Full Article

ImmunoGen Inc reaffirms FY 2015 outlook
Friday, 30 Jan 2015 06:30am EST 

ImmunoGen Inc:Says its financial guidance remains unchanged from that issued in Oct. 2014.Expects FY 2015 revenues to be between $100 mln and $105 mln.Expects FY 2015 net loss to be between $60 mln and $65 mln.FY 2015 net profit of ($60) mln - Thomson Reuters I/B/E/S.  Full Article

BRIEF-Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer

* Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer